Literature DB >> 25750331

Circulating pigment epithelium-derived factor (PEDF) is associated with pathological grade of prostate cancer.

Hisamitsu Ide1, Sho-Ichi Yamagishi2, Yan Lu3, Kentaro Sakamaki4, Akiko Nakajima3, Akira Horiuchi3, Kosuke Kitamura3, Schin-Ichi Hisasue5, Satoru Muto3, Raizo Yamaguchi3, Shigeo Horie5.   

Abstract

BACKGROUND/AIM: Pigment epithelium-derived factor (PEDF) plays a protective role against oxidative stress. Levels of circulating PEDF have not been examined in patients with prostate cancer. We examined whether PEDF can be used to predict the clinical features of prostate cancer prior to therapy.
MATERIALS AND METHODS: Two hundred patients with an abnormal serum level of prostate-specific antigen (PSA) who underwent biopsy between 2008 and 2011 were identified for retrospective analysis. We determined the relationship of the PEDF level to clinical parameters of prostate cancer. We measured levels of PEDF and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in all 200 patients, 100 of whom had histologically-confirmed prostate cancer at the outset. We also investigated the PEDF expression in prostate cancer tissues by immunohistochemistry.
RESULTS: The PEDF level was significantly higher in patients with prostate cancer than in those without. Statistical analysis confirmed that PEDF was significant, positively associated with pathological grading (Gleason score). However, PEDF expression was only detected in few prostate cancer cells by immunohistochemistry. Levels of the oxidative marker, 8-OHdG, in patients with prostate cancer are higher than in those without cancer.
CONCLUSION: Preoperative PEDF measurement in patients with prostate cancer may provide clinically relevant information regarding the pathological grade of tumor. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Gleason score; PEDF; Prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 25750331

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Bioinformatics analysis of differentially expressed proteins in prostate cancer based on proteomics data.

Authors:  Chen Chen; Li-Guo Zhang; Jian Liu; Hui Han; Ning Chen; An-Liang Yao; Shao-San Kang; Wei-Xing Gao; Hong Shen; Long-Jun Zhang; Ya-Peng Li; Feng-Hong Cao; Zhi-Guo Li
Journal:  Onco Targets Ther       Date:  2016-03-16       Impact factor: 4.147

2.  Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.

Authors:  Stanislav Naryzhny; Natalia Ronzhina; Elena Zorina; Fedor Kabachenko; Nikolay Klopov; Victor Zgoda
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

Review 3.  Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review.

Authors:  Louiza Belkacemi; Shaun Xiaoliu Zhang
Journal:  J Exp Clin Cancer Res       Date:  2016-01-08

4.  Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies.

Authors:  Josué Rivera-Pérez; María Del Rocío Monter-Vera; Cornelio Barrientos-Alvarado; Julia D Toscano-Garibay; Teresa Cuesta-Mejías; Javier Flores-Estrada
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.